389 related articles for article (PubMed ID: 21406029)
1. Current and emerging medical therapies in the treatment of glaucoma.
Bagnis A; Papadia M; Scotto R; Traverso CE
Expert Opin Emerg Drugs; 2011 Jun; 16(2):293-307. PubMed ID: 21406029
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cell-based approaches for neuroprotection in glaucoma.
Lebrun-Julien F; Di Polo A
Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Zhong L; Bradley J; Schubert W; Ahmed E; Adamis AP; Shima DT; Robinson GS; Ng YS
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1212-8. PubMed ID: 17325165
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma.
Hains BC; Waxman SG
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.
Jiang C; Moore MJ; Zhang X; Klassen H; Langer R; Young M
Mol Vis; 2007 Sep; 13():1783-92. PubMed ID: 17960131
[TBL] [Abstract][Full Text] [Related]
6. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.
Lambiase A; Aloe L; Centofanti M; Parisi V; Báo SN; Mantelli F; Colafrancesco V; Manni GL; Bucci MG; Bonini S; Levi-Montalcini R
Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13469-74. PubMed ID: 19805021
[TBL] [Abstract][Full Text] [Related]
7. Disease progression and the need for neuroprotection in glaucoma management.
Varma R; Peeples P; Walt JG; Bramley TJ
Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel inhibitors for the treatment of glaucoma.
Cholkar K; Trinh HM; Pal D; Mitra AK
Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective Strategies in Glaucoma.
Gossman CA; Christie J; Webster MK; Linn DM; Linn CL
Curr Pharm Des; 2016; 22(14):2178-92. PubMed ID: 26818878
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma.
Crandall J; Matragoon S; Khalifa YM; Borlongan C; Tsai NT; Caldwell RB; Liou GI
Ophthalmic Res; 2007; 39(2):69-75. PubMed ID: 17284931
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma.
Fu QL; Li X; Yip HK; Shao Z; Wu W; Mi S; So KF
Neuroscience; 2009 Aug; 162(2):375-82. PubMed ID: 19422885
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.
Chen YS; Green CR; Danesh-Meyer HV; Rupenthal ID
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):182-93. PubMed ID: 25676338
[TBL] [Abstract][Full Text] [Related]
13. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
Hernández M; Urcola JH; Vecino E
Exp Eye Res; 2008 May; 86(5):798-806. PubMed ID: 18394603
[TBL] [Abstract][Full Text] [Related]
14. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent.
Bakalash S; Kipnis J; Yoles E; Schwartz M
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2648-53. PubMed ID: 12147598
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment of glaucoma: established and emerging pharmacology.
Dikopf MS; Vajaranant TS; Edward DP
Expert Opin Pharmacother; 2017 Jun; 18(9):885-898. PubMed ID: 28480761
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma.
Chan HC; Chang RC; Koon-Ching Ip A; Chiu K; Yuen WH; Zee SY; So KF
Exp Neurol; 2007 Jan; 203(1):269-73. PubMed ID: 17045262
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo.
Shi Z; Birman E; Saragovi HU
Dev Neurobiol; 2007 Jun; 67(7):884-94. PubMed ID: 17506493
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection in glaucoma: recent and future directions.
Danesh-Meyer HV
Curr Opin Ophthalmol; 2011 Mar; 22(2):78-86. PubMed ID: 21252670
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection in glaucoma - Is there a future role?
Baltmr A; Duggan J; Nizari S; Salt TE; Cordeiro MF
Exp Eye Res; 2010 Nov; 91(5):554-66. PubMed ID: 20800593
[TBL] [Abstract][Full Text] [Related]
20. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
